A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

Platinum is recommended in combination with gemcitabine in the treatment of metastatic triple-negative breast cancer (mTNBC). We conduct a randomized phase 3, controlled, open-label trial to compare nab-paclitaxel/cisplatin (AP) with gemcitabine/cisplatin (GP) in mTNBC patients (ClinicalTrials.gov N...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Biyun, Sun, Tao, Zhao, Yannan, Wang, Shusen, Zhang, Jian, Wang, Zhonghua, Teng, Yue-E, Cai, Li, Yan, Min, Wang, Xiaojia, Jiang, Zefei, Pan, Yueyin, Luo, Jianfeng, Shao, Zhimin, Wu, Jiong, Guo, Xiaomao, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276725/
https://www.ncbi.nlm.nih.gov/pubmed/35821019
http://dx.doi.org/10.1038/s41467-022-31704-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276725/
https://www.ncbi.nlm.nih.gov/pubmed/35821019
http://dx.doi.org/10.1038/s41467-022-31704-7

Ejemplares similares